Skip to main content

Advertisement

Springer Nature Link
Log in

H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series

  • Original Article
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Abstract

Background

Diffuse hemispheric glioma, H3 G34-mutant, is a novel paediatric tumour type in the fifth edition of the WHO classification of CNS tumours associated with an invariably poor outcome. We present a comprehensive clinical, imaging and pathological review of this entity.

Methods

Patients with confirmed H3 G34R-mutant high-grade glioma were included in a single-centre retrospective cohort study and examined for clinical, radiological and histo-molecular data.

Results

Twelve patients were enrolled in the study — 7 males/5 females; the mean age was 17.5 years (10–57 years). Most patients presented with signs of raised intracranial pressure (8/12). The frontal lobe (60%) was the prevalent location, with a mixed cystic-nodular appearance (10/12) and presence of vascular flow voids coursing through/being encased by the mass (8/12), and all tumours showed cortical invasion. Nine patients had subtotal resection limited by functional margins, two patients underwent supra-total resection, and one patient had biopsy only. 5-ALA was administered to 6 patients, all of whom showed positive fluorescence. Histologically, the tumours showed a marked heterogeneity and aggressive spread along pre-existing brain structures and leptomeninges. In addition to the diagnostic H3 G34R/V mutation, pathogenic variants in TP53 and ATRX genes were found in most cases. Potential targetable mutations in PDGFRA and PIK3CA genes were detected in five cases. The MGMT promoter was highly methylated in half of the samples. Methylation profiling was a useful diagnostic tool and highlighted recurrent structural chromosome abnormalities, such as PDGFRA amplification, CDKN2A/B deletion, PTEN loss and various copy number changes in the cyclin D-CDK4/Rb pathway. Radiochemotherapy was the most common adjuvant treatment (9/12), and the average survival was 19.3 months.

Conclusions

H3 G34R-mutant hemispheric glioma is a distinct entity with characteristic imaging and pathological features. Genomic landscaping of individual tumours can offer an opportunity to adapt individual therapies and improve patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Baig Mirza A, Christodoulides I, Lavrador JP et al (2021) 5-Aminolevulinic acid-guided resection improves the overall survival of patients with glioblastoma-a comparative cohort study of 343 patients. Neurooncol Adv 3(1):vdab047

    PubMed  PubMed Central  Google Scholar 

  2. Chen CCL, Deshmukh S, Jessa S et al (2020) Histone H3.3G34-mutant interneuron progenitors co-opt PDGFRA for gliomagenesis. Cell 183(6):1617-1633.e22

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hegi ME, Diserens A-C, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003

    Article  CAS  PubMed  Google Scholar 

  4. Hu W, Duan H, Zhong S, Zeng J, Mou Y (2022) High frequency of PDGFRA and MUC family gene mutations in diffuse hemispheric glioma, H3 G34-mutant: a glimmer of hope? J Transl Med 20(1):64

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kallappagoudar S, Yadav RK, Lowe BR, Partridge JF (2015) Histone H3 mutations–a special role for H3.3 in tumorigenesis? Chromosoma 124(2):177–189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Korshunov A, Capper D, Reuss D et al (2016) Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 131(1):137–146

    Article  CAS  PubMed  Google Scholar 

  7. Kurokawa R, Baba A, Kurokawa M, Pinarbasi ES, Makise N, Ota Y, Kim J, Srinivasan A, Moritani T (2022) Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: a case series and systematic review. J Neuroimaging 32(1):17–27

    Article  PubMed  Google Scholar 

  8. Lee J, Solomon DA, Tihan T (2017) The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children. J Neurooncol 132(1):1–11

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lim KY, Won JK, Park C-K, Kim S-K, Choi SH, Kim T, Yun H, Park S-H (2021) H3 G34-mutant high-grade glioma. Brain Tumor Pathol 38(1):4–13

    Article  CAS  PubMed  Google Scholar 

  10. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131(6):803–820

    Article  PubMed  Google Scholar 

  11. Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231–1251

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Lowe BR, Maxham LA, Hamey JJ, Wilkins MR, Partridge JF (2019) Histone H3 mutations: an updated view of their role in chromatin deregulation and cancer. Cancers (Basel). https://doi.org/10.3390/cancers11050660

    Article  PubMed  Google Scholar 

  13. Lucas C-HG, Mueller S, Reddy A et al (2021) Diffuse hemispheric glioma, H3 G34-mutant: genomic landscape of a new tumor entity and prospects for targeted therapy. Neuro Oncol 23(11):1974–1976

    Article  PubMed  PubMed Central  Google Scholar 

  14. Mackay A, Burford A, Carvalho D et al (2017) Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma. Cancer Cell 32(4):520-537.e5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Mazurowski MA, Desjardins A, Malof JM (2013) Imaging descriptors improve the predictive power of survival models for glioblastoma patients. Neuro Oncol 15(10):1389–1394

    Article  PubMed  PubMed Central  Google Scholar 

  16. Morris M, Driscoll M, Henson JW, Cobbs C, Jiang L, Gocke CD, Chen L, Rodriguez FJ (2020) Low-grade gemistocytic morphology in H3 G34R-mutant gliomas and concurrent K27M mutation: clinicopathologic findings. J Neuropathol Exp Neurol 79(10):1038–1043

    Article  PubMed  Google Scholar 

  17. Picart T, Barritault M, Poncet D et al (2021) Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. Neurooncol Adv 3(1):vdab061

    PubMed  PubMed Central  Google Scholar 

  18. Puntonet J, Dangouloff-Ros V, Saffroy R, Pagès M, Andreiuolo F, Grill J, Puget S, Boddaert N, Varlet P (2018) Historadiological correlations in high-grade glioma with the histone 3.3 G34R mutation. J Neuroradiol 45(5):316–322

    Article  PubMed  Google Scholar 

  19. Roussel MF, Robinson GW (2013) Role of MYC in medulloblastoma. Cold Spring Harb Perspect Med. https://doi.org/10.1101/cshperspect.a014308

    Article  PubMed  PubMed Central  Google Scholar 

  20. Schwartzentruber J, Korshunov A, Liu X-Y et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384):226–231

    Article  CAS  PubMed  Google Scholar 

  21. Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJJ, Perry A (2016) Diffuse midline gliomas with histone H3–K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol 26(5):569–580

    Article  CAS  PubMed  Google Scholar 

  22. Sturm D, Witt H, Hovestadt V et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22(4):425–437

    Article  CAS  PubMed  Google Scholar 

  23. Vettermann FJ, Felsberg J, Reifenberger G et al (2018) Characterization of diffuse gliomas with histone H3–G34 mutation by MRI and dynamic 18F-FET PET. Clin Nucl Med 43(12):895–898

    Article  PubMed  Google Scholar 

  24. Wang Y, Qian T, You G et al (2015) Localizing seizure-susceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping. Neuro Oncol 17(2):282–288

    Article  PubMed  Google Scholar 

  25. Wang L, Shao L, Li H et al (2022) Histone H3.3 G34-mutant diffuse gliomas in adults. Am J Surg Pathol 46(2):249–257

    Article  PubMed  Google Scholar 

  26. Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44(3):251–253

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Yoshimoto K, Hatae R, Sangatsuda Y et al (2017) Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathol 34(3):103–112

    Article  PubMed  Google Scholar 

  28. Zhang R-Q, Shi Z, Chen H et al (2016) Biomarker-based prognostic stratification of young adult glioblastoma. Oncotarget 7(4):5030–5041

    Article  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. José Pedro Lavrador and Zita Reisz equally contributed to this manuscript

Authors and Affiliations

  1. Department of Neurosurgery, King’s College Hospital Foundation Trust, London, UK

    José Pedro Lavrador, Kapil Rajwani, Asfand Baig Mirza, Francesco Vergani, Richard Gullan, Ranjeev Bhangoo, Keyoumars Ashkan, Cristina Bleil & Bassel Zebian

  2. Department of Clinical Neuropathology, King’s College Hospital Foundation Trust, London, UK

    Zita Reisz, Ross Laxton, Andrew King, Istvan Bodi & Safa Al-Saraj

  3. Department of Neuroradiology, King’s College Hospital Foundation Trust, London, UK

    Naomi Sibtain

  4. Molecular Neuropathology, Synnovis at King’s College Hospital Foundation Trust, London, UK

    Barnaby Clark & Ross Laxton

Authors
  1. José Pedro Lavrador
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Zita Reisz
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Naomi Sibtain
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Kapil Rajwani
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Asfand Baig Mirza
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Francesco Vergani
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Richard Gullan
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Ranjeev Bhangoo
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Keyoumars Ashkan
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Cristina Bleil
    View author publications

    You can also search for this author inPubMed Google Scholar

  11. Bassel Zebian
    View author publications

    You can also search for this author inPubMed Google Scholar

  12. Barnaby Clark
    View author publications

    You can also search for this author inPubMed Google Scholar

  13. Ross Laxton
    View author publications

    You can also search for this author inPubMed Google Scholar

  14. Andrew King
    View author publications

    You can also search for this author inPubMed Google Scholar

  15. Istvan Bodi
    View author publications

    You can also search for this author inPubMed Google Scholar

  16. Safa Al-Saraj
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Asfand Baig Mirza.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This paper has not been previously presented or published

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lavrador, J.P., Reisz, Z., Sibtain, N. et al. H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series. Acta Neurochir 165, 1615–1633 (2023). https://doi.org/10.1007/s00701-023-05545-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00701-023-05545-2

Keywords